DCM
PETX

Delpha Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Delpha Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,515
Closed -$18K – 1583
2017
Q4 		$18K Buy
+3,515
New +$21.5K 0.02% 840

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Delpha Capital Management's PETX Position: Q1 2018 in Review

Delpha Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 3,515 shares — an estimated $18K sold.

Delpha Capital Management first reported a position in PETX in Q4 2017 and held it in 1 quarter. The position peaked at $18K in Q4 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Delpha Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 3,515 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $18K.
  • Delpha Capital Management first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Aratana Therapeutics, Inc. position peaked at $18K in Q4 2017.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.